Dr. Wayne Goodman (320x240)
Dr. Wayne Goodman

Dr. Wayne Goodman, professor and chair of psychiatry at Mount Sinai School of Medicine, has been named to lead the Menninger Department of Psychiatry and Behavioral Sciences at Baylor College of Medicine, effective Sept. 1.

Goodman, who specializes in the treatment of obsessive-compulsive disorder, is the principal developer of the Yale-Brown Obsessive Compulsive Scale, the gold standard for assessing the disorder. He is the co-founder of the International OCD Foundation and also is recognized for his work on deep brain stimulation for intractable psychiatric disorders.

“Dr. Goodman’s impressive career and leadership experience combined with an understanding of the College’s strategic vision make him well positioned to direct the Menninger Department of Psychiatry and Behavioral Sciences,” said Dr. Paul Klotman, president, CEO and executive dean at Baylor. “The outstanding faculty of this department have long been a strength at Baylor and I am confident Dr. Goodman will build on this.”

Goodman also was chair of Mount Sinai’s Behavioral Health System, which includes four hospitals and three psychiatry departments. During his tenure, the department of psychiatry at Mount Sinai rose to No. 7 from No. 20 in the nation in National Institutes of Health funding, with more than $25 million annually.

“I’m honored to be named chair of the Menninger Department of Psychiatry and Behavioral Sciences at Baylor,” said Goodman. “There is so much that impresses me about the department’s current strengths and opportunities for further growth. My vision for the department is for it to become a translational research powerhouse as reflected in its level of federal funding. The ultimate measure of success is how well our research and educational programs inform and advance our delivery of quality clinical care to our patients.”

Goodman is a graduate of Columbia University and received his medical degree from Boston University School of Medicine. He completed his internship, residency and research fellowship at Yale University School of Medicine.

Goodman has published more than 300 articles, is a member of the American College of Neuropsychopharmacology and a distinguished fellow of the American Psychiatric Association. He served as chair of the Food and Drug Administration’s Psychopharmacologic Drug Advisory Committee and more recently has been a member of the FDA’s Neurological Advices Advisory Committee. Goodman also previously served as director of the division of adult translational research for the National Institute of Mental Health.